Gerberding Julie L.

SEC source: 0000927653-26-000204 · form4.xml · derivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277

Underlying: Common Stock · 277 shares

Expires not disclosed

F1 · derivative.exercise_date: RSUs granted pursuant to an annual grant under the 2022 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.

F1 · derivative.expiration_date: RSUs granted pursuant to an annual grant under the 2022 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.

SEC source: 0001193125-25-206249 · ownership.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

SEC source: 0001062993-25-013399 · form4.xml · derivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301

Underlying: Common Stock · 301 shares

Expires not disclosed

F1 · derivative.exercise_date: RSUs granted pursuant to an annual grant under the 2022 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.

F1 · derivative.expiration_date: RSUs granted pursuant to an annual grant under the 2022 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.

SEC source: 0000950170-25-089961 · ownership.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,224

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date.

SEC source: 0001062993-25-001942 · form4.xml · derivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176

Underlying: Common Stock · 176 shares

Expires not disclosed

F1 · derivative.exercise_date: RSUs granted to reporting person upon election to the Board pursuant to a prorated annual grant under the 2022 Stock Plan. This grant vests immediately, however receipt of the underlying stock is deferred until the director leaves the Board.

F1 · derivative.expiration_date: RSUs granted to reporting person upon election to the Board pursuant to a prorated annual grant under the 2022 Stock Plan. This grant vests immediately, however receipt of the underlying stock is deferred until the director leaves the Board.

SEC source: 0000950170-25-060559 · ownership.xml · derivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates.

SEC source: 0000899243-23-015284 · doc4.xml · derivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates.

SEC source: 0000899243-22-029529 · doc4.xml · derivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-08-18

F1 · derivative.exercise_date: The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date.

SEC source: 0001209191-22-035497 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto) filed by Cedar Acquisition Corporation ("Merger Subsidiary") in connection with the Agreement and Plan of Merger, dated December 20, 2021 (as it may be amended or supplemented from time to time, the "Merger Agreement"), between Cerner Corporation ("Cerner") and Merger Subsidiary, which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of Cerner common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. On June 7, 2022, Oracle accepted all shares tendered in the Offer.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto) filed by Cedar Acquisition Corporation ("Merger Subsidiary") in connection with the Agreement and Plan of Merger, dated December 20, 2021 (as it may be amended or supplemented from time to time, the "Merger Agreement"), between Cerner Corporation ("Cerner") and Merger Subsidiary, which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of Cerner common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. On June 7, 2022, Oracle accepted all shares tendered in the Offer.

SEC source: 0001127602-22-007008 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,712.138

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 9

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,831

Underlying: Common Stock · 11,414 shares

Expires 2030-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 8

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,698

Underlying: Common Stock · 19,394 shares

Expires 2029-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 7

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,175 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · derivative · entry 6

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,287 shares

Expires 2027-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F3 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 5

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,162.138

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.9050 to $87.9250, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 4

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,432.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 3

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,018.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,624.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028263 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,449.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-034517 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,032

F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 25, 2022 or the calendar day immediately preceding the date of the Cerner Corporation 2022 annual meeting of shareholders.

F2 · balance_after: Includes 3,188 shares of restricted common stock.

SEC source: 0001127602-21-015749 · form4.xml · derivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,796

Underlying: Common Stock · 39,796 shares

Expires 2031-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-008573 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,162.138

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-20-021823 · form4.xml · derivative · entry 4

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,111 shares

Expires 2026-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

SEC source: 0001127602-20-021823 · form4.xml · nonDerivative · entry 3

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,577.138

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-20-021823 · form4.xml · nonDerivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,751.138

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-021823 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,862.138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-032288 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,844

F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 18, 2021 or the calendar day immediately preceding the date of the Cerner Corporation 2021 annual meeting of shareholders.

F2 · balance_after: Includes 3,716 shares of restricted common stock.

SEC source: 0001127602-20-015450 · form4.xml · derivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,226

Underlying: Common Stock · 33,226 shares

Expires 2030-04-30

F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

SEC source: 0001127602-20-009149 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,409.366

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-20-001661 · form4.xml · derivative · entry 5

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,012 shares

Expires 2024-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2015, 5/2/2016 and 5/2/2017.

SEC source: 0001127602-20-001661 · form4.xml · derivative · entry 4

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,536 shares

Expires 2025-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.

SEC source: 0001127602-20-001661 · form4.xml · nonDerivative · entry 3

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,038.366

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.04 to $89.61, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-20-001661 · form4.xml · nonDerivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,111.366

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-001661 · form4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,099.366

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-047284 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,128

F1 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder.

F2 · price: Price reflects a weighted-average price for the transaction. Sale of shares took place at actual prices ranging from $71.82 to $71.83.

F3 · balance_after: Includes 5,056 shares of restricted common stock.

SEC source: 0001209191-19-033874 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,056

F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 21, 2020 or the calendar day immediately preceding the date of the Cerner Corporation 2020 annual meeting of shareholders.

F2 · balance_after: Includes 5,056 shares of restricted common stock.

SEC source: 0001104659-19-027582 · a4.xml · derivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,227

Underlying: Common Stock · 28,227 shares

Expires 2029-05-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.

SEC source: 0001225208-19-003894 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,287.977

F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001225208-18-015319 · doc4.xml · derivative · entry 3

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,111

Underlying: Common Stock · 36,218 shares

Expires 2026-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

SEC source: 0001225208-18-015319 · doc4.xml · nonDerivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,262.984

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.9400 to $75.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001225208-18-015319 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,480.984

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-032281 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 29, 2019 or the calendar day immediately preceding the date of Cerner's 2019 annual meeting of shareholders.

F2 · balance_after: Includes 7,100 shares of restricted common stock.

SEC source: 0001225208-18-009415 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,716.527

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.4500 to $59.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001225208-18-008936 · doc4.xml · derivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,277

Underlying: Common Stock · 29,277 shares

Expires 2028-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

SEC source: 0001225208-18-005015 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,276.846

F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001209191-17-035334 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,400

F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 25, 2018 or the calendar day immediately preceding the date of the Cerner Corporation 2018 annual meeting of shareholders.

F2 · balance_after: Includes 8,400 shares of restricted common stock.

SEC source: 0001225208-17-009433 · doc4.xml · derivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,237

Underlying: Common Stock · 34,237 shares

Expires 2027-05-04

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.

SEC source: 0001225208-17-008903 · doc4.xml · derivative · entry 3

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,092 shares

Expires 2017-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

SEC source: 0001225208-17-008903 · doc4.xml · nonDerivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,338.348

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001225208-17-008903 · doc4.xml · nonDerivative · entry 1

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,416.348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.